Posted by Bill F. on February 27, 1999 at 05:36:15:
In Reply to: Re: Celtrix's SomatoKine Demonstrates Positive Effects in Diabetes Patients posted by Jim Lovejoy on February 27, 1999 at 02:32:46:
I plan to do some research, both as an investor and of course as a close watcher of diabetes technology. Althought they have a burn rate of 1.1 million per quarter, I wonder what revenues they are bringing in.
I will look at this and if I can gleen anything I will report back, hope any others can do the same.
It seems a pump was used, I wonder if Minimed might take an interest. Their stated mission is really diabetes care and treatment, not building pumps, this would seem to fit. BTW, they just received approval on the sensor, this is a very good thing, hats off to Minimed.